The androgen receptor as a therapeutic target in prostate cancer

Bibliography

• KOSARY CL, RIES LAG, MILLER BA, HANKEY BF, HARRASA, EDWARDS BK: SEER Cancer Statistics Review, 1973–1992: Tables and Graphs. National Cancer Institute. NIH Pub. No. 96–2789, Bethesda, MD, USA (1995).
   Google Scholar
• FINNISH CANCER REGISTRY: Cancer incidence inFinland 1995. Cancer Soc. Finland, Pub.No. 58, Helsinki, Finland (1997).
   Google Scholar
• HANKEY BF, FEUER EJ, CLEGG LX et al.: Cancer surveil-lance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J. Natl Cancer Inst. (1999) 91:1017–1024.
   PubMed Web of Science ®Google Scholar
• GITTES RF: Carcinoma of the prostate. N Engl. J. Med. (1991) 24:324:236–245.
   Google Scholar
• •A review on standard treatment of prostate cancer.
   Google Scholar
• STEARNS ME, MCGARVEY T: Prostate cancer: therapeutic, diagnostic, and basic studies. Lab. Invest. (1992) 67:540–552.
   PubMed Web of Science ®Google Scholar
• DEKERNION J, BELLDEGRUN A, NAITOH J: Surgical treatment of localized prostate cancer: indications, technique and results. In: New Perspectives in Prostate Cancer. Belldegrun A, Kirby RS, Oliver T (Eds.), Isis Medical Media Ltd., Oxford, UK (1998):185–203.
   Google Scholar
• HUGGINS C, HODGES CV: Studies on prostate cancer: the effects of castration, of estrogen, and of androgen injection on serum phosphatases in meatstatic carcinoma of prostate. Cancer Res. (1941) 1:293–297.
   Google Scholar
• PALMBERG C, KOIVISTO P, VISAKORPI T, TAMMELA TLJ: PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur. Urol. (1999) 36:191–196.
   PubMed Web of Science ®Google Scholar
• KALLIONIEMI O-P, VISAKORPI T: Genetic basis and clonal evolution of human prostate cancer. Adv. Cancer Res. (1996) 68:225–255.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of the molecular genetics ofprostate cancer.
   Google Scholar
• BEATO M, HERRLICH P, SCHUTZ G: Steroid hormonereceptors: many actors in search of a plot. Cell (1995) 83:851–857.
   PubMed Web of Science ®Google Scholar
• JANNE OA, PALVIMO JJ, KALLIO P, MEHTO M: Androgenreceptor and mechanism of androgen action. Ann. Med. (1993) 25:83–89.
   PubMed Web of Science ®Google Scholar
• KOIVISTO P, KOLMER M, VISAKORPI T, KALLIONIEMI OP:Androgen receptor gene and hormonal therapy failure of prostate cancer. Am. J. Pathol. (1998) 152:1–9.
   PubMed Web of Science ®Google Scholar
• •Review on the AR gene alterations in prostate cancer.
   Google Scholar
• SADI MV, BARRACK ER: Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer (1993) 71:2574–2580.
   PubMed Web of Science ®Google Scholar
• VAN DER KWAST TH, SCHALKEN J, RUIZEVELD DE WINTER JA et al: Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer (1991) 48:189–193.
   PubMed Web of Science ®Google Scholar
• VISAKORPI T, HYYTINEN E, KOIVISTO P et al.: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet. (1995) 9:401–406.
   PubMed Web of Science ®Google Scholar
• ••Finding the AR gene amplification in prostate cancer.
   Google Scholar
• KOIVISTO P, KONONEN J, PALMBERG C et al.: Androgenreceptor gene amplification: a possible molecular mechanism for failure of androgen deprivation therapy in prostate cancer. Cancer Res. (1997) 57:314–319.
   PubMed Web of Science ®Google Scholar
• VISAKORPI T, KALLIONIEMI A, SYVÄNEN A-C et al:Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. (1995) 55:342–347.
   PubMed Web of Science ®Google Scholar
• •First comprehensive analysis of genetic aberrations in prostate cancer by CGH.
   Google Scholar
• NUPPONEN NN, KAKKOLA L, KOIVISTO P, VISAKORPI T: Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am. J Pathol. (1998) 153:141–1488.
   PubMed Web of Science ®Google Scholar
• PALMBERG C, KOIVISTO P, HYYTINEN E et al: Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with nonsteroidal potent antiandrogen `Casodex' (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur. Urol. (1997) 31:216–219.
   PubMed Web of Science ®Google Scholar
• GIOVANNUCCI E, STAMPFER MJ, KRITHIVAS K et al.: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA (1997) 94:3320–3323.
   PubMed Web of Science ®Google Scholar
• •An excellent case-control study on association of germ-line CAG repeats in the AR gene with risk of prostate cancer.
   Google Scholar
• HAKIMI JM, SCHOENBERG MP, RONDINELLI RH, PIANTA-DOSI S, BARRACK ER: Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. UM. Cancer Res. (1997) 3:1599–1608
   Web of Science ®Google Scholar
• INGLES SA, ROSS RK, YU MC et al.: Association ofprostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst. (1997) 89:166–170.
   PubMed Web of Science ®Google Scholar
• BRATT O, BORG A, KRISTOFFERSSON U, LUNDGREN R, ZHANG QX, OLSSON H: CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br. J. Cancer (1999) 81:672–676.
   PubMed Web of Science ®Google Scholar
• CORREA-CERRO L, WOHR G, HAUSSLER J, et al.:(CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur. J. Hum. Genet. (1999) 7:357–362.
   PubMed Web of Science ®Google Scholar
• TILLEY WD, BUCHANAN G, HICKEY TE, BENTEL JM: Mutations in the androgen receptor gene are associ-ated with progression of human prostate cancer to androgen independence. Clin. Cancer Res. (1996) 2:277–285.
   PubMed Web of Science ®Google Scholar
• GADDIPATI JP, MCLEOD DG, HEIDENBERG HB et al.:Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. (1994) 54:2861–2864.
   PubMed Web of Science ®Google Scholar
• ELO JP, KVIST L, LEINONEN K et al: Mutated humanandrogen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J. Clin. Endocrinol Metab. (1995) 80:3494–3500.
   PubMed Web of Science ®Google Scholar
• SUZUKI H, AKAKURA K, KOMIYA A, AIDA S, AKIMOTO S, SHIMAZAKI J: Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate (1996) 29:153–158.
   PubMed Web of Science ®Google Scholar
• SUZUKI H, SATO N, WATABE Y, MASAI M, SEINO S, SHIMAZAKI J: Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol. (1993) 46:759–765.
   PubMed Web of Science ®Google Scholar
• EVANS BAJ, HARPER ME, DANIELLS CE et al. Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand confor-mation polymorphism analysis. Prostate (1996) 28 162–171
   PubMed Web of Science ®Google Scholar
• WATANABE M, USHIJIMA T, SHIRAISHI T et al: Geneticalterations of androgen receptor gene in japanese human prostate cancer. Jpn. J. Clin. Oncol (1997) 27:389–393.
   PubMed Web of Science ®Google Scholar
• RUIZEVELD DE, WINTER JA, JANSSEN PJA et al.:Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am. J. Pathol. (1994) 144:735–746.
   PubMed Web of Science ®Google Scholar
• WALLEN MJ, LINJA M, KAARTINEN K, SCHLEUTKER J, VISAKORPI T: Androgen receptor gene mutations in hormone-refractory prostate cancer. J. Pathol. (1999) 189:559–563.
   PubMed Web of Science ®Google Scholar
• TAPLIN M-E, BUBLEY GJ, SHUSTER TD et al: Mutation ofthe androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl. J. Med. (1995) 332:1393–1398.
   PubMed Web of Science ®Google Scholar
• TAPLIN ME, BUBLEY GJ, KO YJ et al.: Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. (1999) 59:2511–2515.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates the association of flutamide treatment withmutations in codon 877 of the AR gene.
   Google Scholar
• ANZICK SL, KONONEN J, WALKER RL et al.: AIB1, asteroid receptor coactivator amplified in breast and ovarian cancer. Science (1997) 277:965–968.
   PubMed Web of Science ®Google Scholar
• LEE SK, ANZICK SL, CHOI JE et al.: A nuclear factor, ASC-2, as a cancer-amplified transcriptional coacti-vator essential for ligand-dependent transactivation by nuclear receptors in vivo. J. Biol. Chem. (1999) 274:34283–34293.
   PubMed Web of Science ®Google Scholar
• HSIAO PW, CHANG C: Isolation and characterization ofARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells. J. Biol. Chem. (1999) 274:22373–22379.
   PubMed Web of Science ®Google Scholar
• KANG HY, YEH S, FUJIMOTO N, CHANG C: Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J. Biol. Chem. (1999) 274:8570–8576.
   PubMed Web of Science ®Google Scholar
• FUJIMOTO N, YEH S, KANG HY: Cloning and characteri-zation of androgen receptor coactivator, ARA55, in human prostate. J. Biol. Chem. (1999) 274:8316–8321.
   PubMed Web of Science ®Google Scholar
• YEH S, MIYAMOTO, H., NISHIMURA K et al.: Retinoblas-toma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochem. Biophys. Res. Commun. (1998) 248:361–367.
   PubMed Web of Science ®Google Scholar
• YEH S, CHANG C: Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc. Natl Acad. Sci. USA (1996) 93:5517–5521.
   PubMed Web of Science ®Google Scholar
• •Cloning the ARA70 gene.
   Google Scholar
• MOILANEN AM, KARVONEN U, POUKKA H et al: A testis-specific androgen receptor coregulator that belongs to a novel family of nuclear proteins. J. Biol. Chem. (1999) 274:3700–3704.
   PubMed Web of Science ®Google Scholar
• MOILANEN AM, KARVONEN U, POUKKA H, ANNE OA, PALVIMO JJ: Activation of androgen receptor function by a novel nuclear protein kinase. Mol. Biol. Cell (1998) 9:2527–2543.
   PubMed Web of Science ®Google Scholar
• MOILANEN AM, POUKKA H, KARVONEN U, HAKLI M, ANNE OA, PALVIMO JJ: Identification of a novel RING finger protein as a coregulator in steroid receptor-mediated gene transcription. Mol. Cell Biol. (1998) 18:5128–5139.
   PubMed Web of Science ®Google Scholar
• MIYAMOTO H, YEH S, WILDING G, CHANG C: Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc. Natl. Acad Sci. USA (1998) 95:7379–7384.
   PubMed Web of Science ®Google Scholar
• ••Thorough evaluation of the effect of ARA70 expression onactivity of AR.
   Google Scholar
• CULIG Z, HOBISCH A, CRONAUER MV et al: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. (1994) 54:5474–5478.
   PubMed Web of Science ®Google Scholar
• •Study on AR activation by different growth factors.
   Google Scholar
• KLEIN KA, REITER RE, REDULA J et al.: Progression ofmetastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Med. (1997) 3:402–408.
   PubMed Web of Science ®Google Scholar
• CRAFT N, SHOSTAK Y, CAREY M, SAWYERS CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med. (1999) 5:280–285.
   PubMed Web of Science ®Google Scholar
• ••An excellent study about the cross-talk between ERBB2 andAR pathway.
   Google Scholar
• YEH S, UN HK, KANG HY, THIN TH, UN MF, CHANG C: From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA (1999) 96:5458–5463.
   PubMed Web of Science ®Google Scholar
• •Demonstrates cross-tak between ERBB2 and AR signalling pathways.
   Google Scholar
• SLAMON DJ, CLARK GM, WONG SG, LEVIN WJ, ULLRICHA, MCGUIRE WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235:177–182
   PubMed Web of Science ®Google Scholar
• BUBENDORF L, KONONEN J, KOIVISTO P et al.: Survey ofgene amplifications during prostate cancer progres-sion by high-throughout fluorescence in situ hybridi-zation on tissue microarrays. Cancer Res. (1999) 59:803–806.
   PubMed Web of Science ®Google Scholar
• •High througput analysis of gene amplification in prostate cancer.
   Google Scholar
• CRAWFORD ED, EISENBERGER MA, MCLEOD DG et al: Acontrolled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl. J. Med. (1989) 321:419–424.
   PubMed Web of Science ®Google Scholar
• EISENBERGER MA, BLUMENSTEIN BA, CRAWFORD ED et al.: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl. J. Med. (1998) 339:1036–1042.
   PubMed Web of Science ®Google Scholar
• •Clinical trial on efficacy of maximal androgen blockade in treatment of prostate cancer.
   Google Scholar
• PANTEL, K, ENZMANN T, KOLLERMANN J, CAPRANO J, RIETHMULLER G, KOLLERMANN MW: Immunocyto-chemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation. Int. J. Cancer (1997) 71:521–525.
   PubMed Web of Science ®Google Scholar
• COBLEIGH MA, VOGEL CL, TRIPATHY D et al: Multina-tional study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol (1999) 17:2639–2648.
   PubMed Web of Science ®Google Scholar
• AGUS DB, SCHER HI, HIGGINS B et al.: Response ofprostate cancer to anti-Her-2/neu antibody in androgen-dependent and-independent human xenograft models. Cancer Res. (1999) 59:4761–4764.
   PubMed Web of Science ®Google Scholar
• •A xenograft study on the use of trastuzumab for treatment in prostate cancer.
   Google Scholar